Evaluation of safety, efficacy, and other clinical endpoints of delta-9-tetrahydrocannabinol in older patients with hem/onc malignancies. This is an ASCO Meeting Abstract from the 2017 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback